Bronstein, Gewirtz & Grossman, LLC Investigates China-Biotics, Inc.
July 01 2011 - 11:54AM
Business Wire
Bronstein, Gewirtz & Grossman, LLC is investigating
potential claims on behalf of purchasers of the securities of
China-Biotics, Inc. (“China Biotics” or the “Company”) (NASDAQ GS:
CHBT), concerning whether the company and certain of its officers
and directors have violated federal securities laws.
On June 15, 2011, NASDAQ halted trading in China-Biotics common
stock, a leading developer, manufacturer, and distributor of
probiotics products in China. The Company filed for an extension of
time to file with the Securities and Exchange Commission its Annual
Report on Form 10-K for the fiscal year ended March 31, 2011.
NASDAQ has requested that China-Biotics provide certain information
and explanation relating to the Company’s delay in filing the Form
10-k.
If you are aware of any facts relating to this investigation, or
purchased shares of China- Biotics, you can assist this
investigation by contacting either Peretz Bronstein or Eitan
Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484
or via email eitan@bgandg.com. Those who inquire by e-mail are
encouraged to include their mailing address and telephone
number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation
boutique. Our primary expertise is the aggressive pursuit of
litigation claims on behalf of our clients. In addition to
representing institutions and other investor plaintiffs in class
action security litigation, the firm’s expertise includes general
corporate work, private securities offerings, and securities
arbitration.
China-Biotics, Inc. (MM) (NASDAQ:CHBT)
Historical Stock Chart
From Jun 2024 to Jul 2024
China-Biotics, Inc. (MM) (NASDAQ:CHBT)
Historical Stock Chart
From Jul 2023 to Jul 2024